Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2 Gene Therapy
/PRNewswire/ -- Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the United...